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Abstract 
 
Background: The study aimed to investigate the role of medical history (skin warts, Candida 
albicans, herpetic lesions, heartburn, regurgitation) and medication use (for heartburn; for 
regurgitation; aspirin) in the aetiology of upper aerodigestive tract (UADT) cancer.  
Methods: A multicentre (10 European countries) case–control study [Alcohol-Related CAncers and 
GEnetic susceptibility (ARCAGE) project].  
Results: There were 1779 cases of UADT cancer and 1993 controls. History of warts or C. albicans 
infection was associated with a reduced risk [odds ratio (OR) 0.80, 95% confidence interval (CI) 
0.68–0.94 and OR 0.73, 95% CI 0.60–0.89, respectively] but there was no association with herpetic 
lesions, heartburn, regurgitation or medication for related symptoms. Regurgitation was associated 
with an increased risk for cancer of the oesophagus (OR 1.47, 95% CI 0.98–2.21). Regular aspirin 
use was not associated with risk of UADT cancer overall but was associated with a reduced risk for 
cancer of oesophagus (OR 0.51, 95% CI 0.28–0.96), hypopharynx (OR 0.53, 95% CI 0.28–1.02) 
and larynx (OR 0.74, 95% CI 0.54–1.01).  
Conclusions: A history of some infections appears to be a marker for decreased risk of UADT 
cancer. The role of medical history and medication use varied by UADT subsites with aspirin use 
associated with a decreased risk of oesophageal cancer and suggestive of a decreased risk of 
hypopharyngeal and laryngeal cancers.  
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Introduction 
Cancer of the upper aerodigestive tract (UADT) (oral cavity, pharynx, larynx and oesophagus 
combined) is, globally, the fourth most common cancer and cause of cancer mortality, with an 
estimated 1 033 004 incident cases and 712 489 deaths in 2008 [1]. While a decrease in mortality 
was noted in the European Union overall between 1993 and 2004, a persistent rise was observed in 
central and eastern European countries [2].  
Major risk factors for UADT cancer are tobacco consumption, heavy alcohol drinking and poor 
nutrition, specifically low fruit and vegetable consumption [3–5]. Other possible risk factors include 
poor oral hygiene, alcohol in mouthwash and genetic factors [6].  
Human papillomavirus (HPV) has been shown to play an aetiological role in head and neck cancers 
irrespective of tobacco and alcohol use [7–10] and may be responsible for the increase in incidence 
of oropharyngeal squamous cell carcinoma (SCC) [11]. A systematic review by Kreimer et al. [12] 
of 60 studies estimated that the prevalence of HPV in head and neck SCC specimens was 25.9% 
(95% CI 24.7–27.2). In clinical practise, only oropharyngeal (tonsil/base of tongue) cancers are 
tested for HPV [13].  
Other aspects of medical history have been investigated, such as self-reported history of warts, 
herpetic lesions and yeast infection [14–18] and symptoms of gastrointestinal reflux [9, 19], but 
there have been few studies and the results are inconsistent. The herpes simplex virus (HSV) type 1 
has been associated with oral cancer by serological studies, animal models and in vitro systems 
[20]. It is likely that HSV, similar to HPV, is transmitted to the oral cavity by orogenital contact 
[21]. Infection with Candida has been associated with malignant development in the oral cavity by 
means of endogenous nitrosamine production [15, 22].  
Quantitative review of aspirin and cancer risk found reduction in risk for several cancer sites; 
however, there was evidence of significant heterogeneity between studies, with a stronger reduction 
in risk in case–control studies compared with cohort studies [23]. Recent analysis of individual 
patient data from randomised clinical trials of daily aspirin [24] showed a significant reduction in 
the number of deaths due to cancer. Few studies have investigated the role of nonsteroidal anti-
inflammatory drugs (NSAIDs) specifically for UADT cancer [25–27] and the results are not 
consistent. Biologically, aspirin and other NSAIDs suppress the production of prostaglandins and 
thromboxanes by irreversible inactivation of the cyclooxygenase (COX) enzyme that is involved in 
mechanism of carcinogenesis [28].  
The aim of this study, the largest among UADT cancer studies ever conducted in Europe, is to 
further investigate the effect of previous verrucae/warts infection, HSV and Candida infection, 
symptoms of gastrointestinal reflux and associated use of medication or aspirin on the risk of 
UADT cancer.  
 
Methods 
The Alcohol-Related CAncers and GEnetic Susceptibility (ARCAGE) project is a large multicentre 
case–control study conducted in 14 European centres (in 10 countries) and coordinated by the 
International Agency for Research on Cancer (IARC) (http://www.iarc.fr/). It was designed to 
examine the environmental and genetic risk factors for UADT cancers in adults [29]. Cases are 
cancers of the UADT, i.e. those of the oral cavity, pharynx (other than nasopharynx), larynx and 
oesophagus [i.e. International Classification of Disease, Revision 10 (ICD-10: 
http://www.who.int/classifications/icd/en/) C01-06, C08-10, C13-15, C32]. Cases were identified 
from participating hospitals as soon as possible after the diagnosis was made, and in no instance 
later than 6 months after diagnosis.  
In each centre, controls were frequency-matched to cases by sex and age (within 5 years). In most 
centres, controls were chosen from subjects admitted as inpatients or attending outpatient 
departments in the same hospital as the cases. Admission diagnoses related to alcohol, tobacco or 
dietary factors were excluded. Only controls with a recently diagnosed disease were accepted; 
patients who have been in the hospital for >1 week were not included to avoid oversampling of 
long-stay patients. The proportion of controls within a specific diagnostic group did not exceed 33% 
of the total. The UK centres used population controls who were randomly chosen from the same 
family medical practise list as the corresponding case. Specifically, for each case, a total of 10 
controls were selected. The potential controls were approached in random order and, in case of non-
participation of the first potential control, the second one was approached and so on until one 
agreed to participate.  
The ARCAGE project was approved by the Ethical Review Board of IARC, as well as the 
respective local boards in the individual participating centres. All subjects provided written 
informed consent for their participation in the study. Both cases and controls were interviewed, 
during which time they completed a common lifestyle questionnaire. The questionnaire collected 
details on sociodemographic factors and anthropometry, smoking history, alcohol consumption, 
dietary habits (consumption of fruits, vegetables and meat), oral health, medical history and 
medication use. Specifically, participants were asked if, throughout their lives, they had ever had 
any of the following:  
• Skin warts/verrucae, C. albicans/thrush or herpetic lesions/cold sores. Information was also 
obtained on infection location, i.e. hands, feet, head and neck, genital region or other (open 
question).  
• Heartburn or regurgitation (including frequency and age of commencement) and medication 
use for these conditions. 
• Regular aspirin use (at least once a week for a year). Information was obtained on duration 
of use. The Paris centre did not collect information on medical history as described above, 
however participants were asked whether they regularly had migraines and, in case of a 
positive reply, to indicate the names and duration of drugs used.  
STATA 11.0 for Windows [30] was used for statistical data analysis. Unconditional logistic 
regression models were used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for 
UADT cancer. Multinomial regression models (mlogit procedure in STATA) were used to estimate 
the ORs for each cancer site. The models were adjusted for the following variables: centre, sex, age, 
education, smoking (pack-years), alcohol consumption (alcohol drink-years), fruit intake 
(frequency) and body mass index (BMI). Further analysis was carried out adjusting history of skin 
warts/verrucae, C. albicans/thrush or herpetic lesions/cold sores for each other in addition to other 
adjustment variables. Heartburn or regurgitation was also adjusted for aspirin use, in addition to 
other adjustment variables.  
 
Results 
The overall participation rate was 82% among cases and 68% among controls. However, 
participation rate was low among population controls (26%–35%). In some centres, cases and 
controls explicitly refused any recording of information and therefore were not included into the 
participants’ database, leading to an overestimated participation rate [29].  
The distribution of the hospital controls by diagnostic group was as follows: acute gastrointestinal 
conditions (19%), injuries (17%), eye, ear or related conditions (14%), musculoskeletal, connective 
tissue and skin disorders (13%), genitourinary system conditions (10%), respiratory diseases (9%), 
neurological conditions and behavioural disorders (5%), abnormal laboratory tests or unspecified 
symptoms and signs or other complaints leading to seeking medical advice (4%), benign neoplasms 
(3%), circulatory system diseases (3%), endocrine conditions (1%), infectious diseases and 
congenital malformations (2%) [29]. Only 32 (2%) hospital controls had diseases of the skin and 
subcutaneous tissue.  
In total, there were 1779 cases of UADT cancers (all SCC) available for current analysis and 1993 
controls (Table 1).  
 
Table 1.  
Distribution of UADT cases and controls by centre and subsite 
Centre Controls Cases Cases by subsite (all SCC) 
   Oral cavity Oropharynx Hypopharynx OP NOSa Larynx Oesophagus 
Czech Republic—Prague 187 163 5 49 11 8 41 49 
Germany—Bremen 328 277 53 96 40 6 72 10 
Greece—Athens 194 211 51 14 1 34 102 9 
Italy—Aviano 151 145 48 34 9 1 36 17 
Italy—Padova 130 128 26 24 13 0 51 14 
Italy—Turin 198 157 65 28 9 2 41 12 
Ireland—Dublin 19 33 7 6 5 0 5 10 
Norway—Oslo 184 137 39 45 11 1 30 11 
UK—Glasgow 91 86 15 23 8 21 18 1 
UK—Manchester 186 141 63 40 9 9 20 0 
UK—Newcastle 113 67 17 7 4 9 19 11 
Spain—Barcelona 166 184 42 34 17 3 79 9 
Croatia—Zagreb 46 50 30 12 6 0 2 0 
France—Paris 234 323 49 62 40 18 154 0 
TOTAL 2227 2102 510 474 183 112 670 153 
 
SCC, squamous cell carcinoma; UADT, upper aerodigestive tract. 
a Oral, pharynx not otherwise specified.  
 
The prevalence of skin warts/verrucae was 36% among cases and 45% among controls, C. 
albicans/thrush 16% and 23%, respectively and herpetic lesions (cold sores) 38% and 43%, 
respectively (Table 2). Having had warts/verrucae or C. albicans/thrush infection was associated 
with a reduced risk for UADT cancers (OR 0.80, 95% CI 0.68–0.94 and OR 0.73, 95% CI 0.60–
0.89, respectively) but there was no association with herpetic lesions (OR 0.96, 95% CI 0.82–1.12) 
(Table 2). When considered by location, a reduced risk was found for foot skin warts/verrucae (OR 
0.70, 95% CI 0.53–0.93), head and neck (OR 0.67, 95% CI 0.49–0.90) and genitals (OR 0.31, 95% 
CI 0.10–0.90). For history of C. albicans/thrush infection, reduced risk was noted for infection in 
the genitals (OR 0.67, 95% CI 0.49–0.92) and nonsignificant reduced risk for infection in the mouth 
(OR 0.86, 95% CI 0.59–1.24). Further analysis adjusting history of skin warts/verrucae, C. 
albicans/thrush or herpetic lesions/cold sores for each other in addition to other adjustment 
variables did not show substantial change in risk estimate (Table 2). 
 
Table 2.  
Skin warts/verrucae, Candida albicans/thrush, Herpetic lesions (cold sore) and UADT cancer risk  
Characteristics Casesa Controlsa OR (95% CI)b 
 N (%)  N (%)   
Skin warts/verrucae 
Never     1119 (63.80) 1077 (55.75) 1.00 
Ever     635 (36.20) 890 (45.25) 0.80 (0.68, 0.94) 
Skin warts/verrucae (location)c 
Hands     433 (24.69) 559 (28.42) 0.84 (0.70–1.01) 
Feet     125 (7.13) 230 (11.69) 0.70 (0.53–0.93) 
Head     & Neck 109 (6.21) 172 (8.74) 0.67 (0.49–0.90) 
Genitals     6 (0.34) 15 (0.76) 0.31 (0.10–0.90) 
C. albicans/thrush  
Never     1457 (83.83) 1507 (76.85) 1.00 
Ever     281 (16.17) 454 (23.15) 0.73 (0.60–0.89) 
C. albicans/thrush (location)c 
Genitals     93 (5.35) 173 (8.82) 0.67 (0.49–0.92) 
Mouth     80 (4.60) 101 (5.15) 0.86 (0.59–1.24) 
Herpetic lesions (cold sore) 
Never     1075 (61.75) 1118 (56.84) 1.00 
Ever     666 (38.25) 849 (43.16) 0.96 (0.82–1.12) 
Herpetic lesions (location)c 
    Lip 600 (34.46) 773 (39.30) 0.97 (0.83–1.14) 
Genitals     12 (0.69) 14 (0.71) 1.06 (0.44–2.50) 
Additional modeld 
Skin warts/verrucae     612 (36.15) 874 (45.31) 0.81 (0.69–0.96) 
    C. albicans/thrush  273 (16.13) 446 (23.12) 0.76 (0.62–0.94) 
Herpetic lesions (cold sore)     652 (38.51) 841 (43.60) 0.99 (0.84–1.16) 
 
CI, confidence interval; OR, odds ratio; UADT, upper aerodigestive tract. 
a Numbers do not add up to total due to missing values.  
b Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), 
fruit consumption and body mass index 2 years ago.  
c Reference category ‘never’; Categories are not mutually exclusive.  
d Reference category ‘never’; Adjusted for each other in addition to b.  
 
Heartburn was reported by 48% of cases and 48% of controls, while regurgitation was reported by 
19% of cases and 20% of controls. Symptoms of gastro-oesophageal reflux were not associated 
with risk of UADT cancer (OR for heartburn 0.90, 95% CI 0.77–1.04 and OR for regurgitation 
0.88, 95% CI 0.73–1.07, respectively) (Tables 3 and 4). There was no change in risk with longer 
duration of heartburn. Younger age at the onset of heartburn symptoms (<25 years), shorter (<10 
years) or longer (≥35 years) time between heartburn symptoms start and diagnosis and medication 
use for heartburn were associated with reduced risk (OR 0.68, 95% CI 0.54–0.89; OR 0.76, 95% CI 
0.58–0.98; OR 0.74, 95% CI 0.57–0.95; and OR 0.81, 95% CI 0.68–0.96, respectively). There was 
no association with regurgitation frequency, age at regurgitation onset, time between regurgitation 
symptoms start and diagnosis or medication use of regurgitation (Table 4). Additional adjustment 
for aspirin use did not show change in risk estimates (Tables 3 and 4). 
 
Table 3.  
Heartburn and UADT cancer risk 
Characteristics Casesa Controlsa OR (95% CI)b OR (95% CI)c 
 N (%)  N (%)    
Heartburn 
Never     932 (52.54) 1040 (52.34) 1.00 1.00 
Ever     842 (47.46) 947 (47.66) 0.90 (0.77–1.04) 0.89 (0.71–1.09) 
Heartburn frequency 
No heartburn     932 (53.29) 1040 (52.66) 1.00 1.00 
Less than once per week     350 (20.01) 424 (21.47) 0.85 (0.70–1.04) 0.85 (0.70–1.04) 
Once per week     116 (6.63) 117 (5.92) 0.99 (0.72–1.35) 0.98 (0.72–1.34) 
2–6 times per week     160 (9.15) 203 (10.28) 0.81 (0.62–1.05) 0.80 (0.62–1.04) 
At least once a day     191 (10.92) 191 (9.67) 0.97 (0.75–1.25) 0.96 (0.75–1.25) 
Age began suffering from heartburn (years) 
No heartburn     932 (55.44) 1040 (53.75) 1.00 1.00 
    <25 159 (9.46) 207 (10.70) 0.68 (0.54–0.89) 0.68 (0.52–0.88) 
25–34     205 (12.20) 239 (12.35) 0.89 (0.70–1.13) 0.88 (0.69–1.13) 
35–44     169 (10.05) 191 (9.87) 0.89 (0.68–1.16) 0.88 (0.68–1.15) 
45+     216 (12.85) 258 (13.33) 0.95 (0.75–1.21) 0.95 (0.75–1.21) 
Time between heartburn start and diagnosis (years) 
No heartburn     932 (55.44) 1040 (53.75) 1.00 1.00 
0–9     152 (9.04) 215 (11.11) 0.76 (0.58–0.98) 0.75 (0.57–0.98) 
10–21     200 (11.90) 237 (12.25) 0.97 (0.76–1.24) 0.97 (0.76–1.23) 
22–34     215 (12.79) 228 (11.78) 0.96 (0.76–1.23) 0.96 (0.75–1.22) 
35+     182 (10.83) 215 (11.11) 0.74 (0.57–0.95) 0.74 (0.57–0.95) 
Medication for heartburn 
No heartburn     932 (53.01) 1040 (52.58) 1.00 1.00 
No     343 (19.51) 320 (16.18) 1.06 (0.86–1.30) 1.05 (0.85–1.30) 
Yes     483 (27.47) 618 (31.24) 0.81 (0.68–0.96) 0.81 (0.68–0.96) 
 
CI, confidence interval; OR, odds ratio; UADT, upper aerodigestive tract. 
a Numbers do not add up to total due to missing values.  
b Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), 
fruit consumption and body mass index 2 years ago.  
c Adjusted for aspirin use (never/ever) in addition to b.  
 
Table 4.  
Regurgitation and UADT cancer risk 
Characteristics Casesa Controlsa OR (95% CI)b OR (95% CI)bc 
 N (%)  N (%)    
Regurgitation 
Never     1439 (81.39) 1588 (80.53) 1.00 1.00 
Ever     329 (18.61) 384 (19.47) 0.88 (0.73–1.07) 0.88 (0.71–1.10) 
Characteristics Casesa Controlsa OR (95% CI)b OR (95% CI)bc 
 N (%)  N (%)    
Regurgitation frequency 
Never     1439 (81.95) 1588 (80.86) 1.00 1.00 
Less than once per week   163 (9.28) 181 (9.22) 0.96 (0.74–1.25) 0.96 (0.74–1.25) 
Once per week     34 (1.94) 47 (2.39) 0.70 (0.42–1.16) 0.70 (0.42–1.17) 
2–6 times per week     46 (2.62) 59 (3.00) 0.72 (0.46–1.15) 0.71 (0.45–1.12) 
At least once a day     74 (4.21) 89 (4.59) 0.91 (0.62–1.32) 0.91 (0.63–1.33) 
Age regurgitation began (years) 
No regurgitation     1439 (83.61) 1588 (82.07) 1.00 1.00 
55+     53 (3.08) 81 (4.19) 0.74 (0.49–1.13) 0.75 (0.49–1.14) 
45–54     52 (3.02) 65 (3.36) 0.91 (0.60–1.40) 0.93 (0.61–1.42) 
35–44     61 (3.54) 65 (3.36) 0.97 (0.64–1.47) 0.96 (0.63–1.47) 
25–34     55 (3.20) 67 (3.46) 0.86 (0.56–1.32) 0.86 (0.53–1.31) 
    <25 61 (3.54) 69 (3.57) 0.75 (0.49–1.13) 0.74 (0.48–1.12) 
Time between regurgitation start and diagnosis (years) 
No regurgitation     1439 (83.61) 1588 (82.07) 1.00 1.00 
0–6     64 (3.72) 93 (4.81) 0.70 (0.48–1.02) 0.71 (0.49–1.03) 
7–17     63 (3.66) 85 (4.39) 0.96 (0.65–1.43) 0.97 (0.66–1.44) 
18–31     80 (4.65) 87 (4.50) 0.87 (0.61–1.25) 0.87 (0.61–1.26) 
32+     75 (4.36) 82 (4.24) 0.86 (0.59–1.25) 0.85 (0.58–1.24) 
Medication for regurgitation 
No regurgitation     1439 (82.18) 1588 (80.90) 1.00 1.00 
No     216 (12.34) 229 (11.67) 0.92 (0.73–1.17) 0.92 (0.73–1.17) 
Yes     96 (5.48) 146 (7.44) 0.76 (0.55–1.04) 0.76 (0.55–1.04) 
 
CI, confidence interval; OR, odds ratio; UADT, upper aerodigestive tract. 
a Numbers do not add up to total due to missing values.  
b Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), 
fruit consumption and body mass index 2 years ago.  
cAdjusted for aspirin use (never/ever) in addition to b.  
 
Regular aspirin use (at least once a week for a year) was reported by 13% of cases and 16% of 
controls and was associated with borderline reduced risk of UADT cancer (OR 0.87, 95% CI 0.70–
1.09) (Table 5). There was no difference in risk by age when regular aspirin use stopped and 
duration of use; however, there was a decrease in risk among those who started using aspirin 
regularly at 55–64 years of age (OR 0.60, 95% CI 0.40–0.89) in comparison to those who never 
used aspirin at least once a week for a year. Cases were more likely to have stopped taking aspirin 
regularly within a year before interview (OR 0.68, 95% CI 0.51–0.91). When considering aspirin 
use for migraines (Paris centre only), a reduced risk was observed for aspirin use (OR 0.22, 95% CI 
0.10–0.51). When considered by duration of use, significant decrease in risk was observed for 
whose who used aspirin for migraines for <5 years (OR 0.26, 95% CI 0.10–0.65) and for those who 
used it for 5–30 years (OR 0.13, 95% CI 0.02–0.80) compared with those with no migraines. 
 
Table 5.  
Aspirin use and UADT cancer risk 
Characteristics Casesa Controlsa OR (95% CI)b 
 N (%)  N (%)   
Aspirin use (at least once a week for a year) 
Never     1527 (86.66) 1649 (83.71) 1.00 
Characteristics Casesa Controlsa OR (95% CI)b 
 N (%)  N (%)   
Ever     235 (13.34) 321 (16.29) 0.87 (0.70–1.09) 
Age began using (years) 
Never     1527 (87.46) 1649 (84.13) 1.00 
    <45 79 (4.52) 91 (4.64) 1.11 (0.78–1.58) 
45–54     49 (2.81) 64 (3.27) 0.77 (0.50–1.20) 
55–64     54 (3.09) 90 (4.59) 0.60 (0.40–0.89) 
65+     37 (2.12) 66 (3.37) 0.93 (0.57–1.50) 
Age stopped using (years) 
Never     1527 (89.25) 1649 (85.53) 1.00 
    <45 18 (1.05) 20 (1.04) 1.46 (0.70–3.04) 
45–54     26 (1.52) 38 (1.97) 0.80 (0.44–1.45) 
55–64     66 (3.86) 89 (4.62) 0.70 (0.48–1.02) 
65+     74 (4.32) 132 (6.85) 0.78 (0.55–1.16) 
Duration of use (years) 
Never     1527 (89.30) 1649 (85.53) 1.00 
    <5 80 (4.68) 127 (6.59) 0.81 (0.58–1.13) 
5–9     42 (2.46) 65 (3.37) 0.78 (0.49–1.22) 
10+     61 (3.57) 87 (4.51) 0.78 (0.53–1.15) 
Time between start using and diagnosis (years) 
Never     1527 (87.61) 1649 (84.39) 1.00 
1–3     43 (2.47) 70 (3.58) 0.80 (0.51–1.25) 
4–9     57 (3.27) 96 (4.91) 0.73 (0.49–1.08) 
10–21     53 (3.04) 70 (3.58) 0.82 (0.54–1.25) 
22+     63 (3.61) 69 (3.53) 1.13 (0.76–1.70) 
Time since stopped using (years) 
Never     1527 (89.25) 1649 (85.53) 1.00 
    <1 109 (6.37) 190 (9.85) 0.68 (0.51–0.91) 
1–4     42 (2.45) 52 (2.70) 0.97 (0.59–1.60) 
5+     33 (1.93) 37 (1.92) 1.20 (0.69–2.09) 
Migraines and aspirin usec 
No migraines     305 (94.43) 195 (85.15) 1.00 
Aspirin     15 (4.64) 32 (13.97) 0.22 (0.10–0.51) 
Other medication     3 (0.93) 2 (0.87) 0.33 (0.03–4.34) 
Migraines and aspirin use (duration of use, years)c 
No migraines     305 (94.43) 195 (85.15) 1.00 
    <5 12 (3.72) 22 (9.61) 0.26 (0.10–0.65) 
5–30     3 (0.93) 10 (4.34) 0.13 (0.02–0.80) 
Other medication     3 (0.93) 2 (0.87) 0.33 (0.03–4.31) 
 
CI, confidence interval; OR, odds ratio; UADT, upper aerodigestive tract. 
a Numbers do not add up to total due to missing values.  
b Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), 
fruit consumption and body mass index 2 years ago.  
c France (Paris) centre only.  
 
When considered by type of UADT cancer, regular aspirin use was associated with a reduced risk 
for cancer of the oesophagus (OR 0.51, 95% CI 0.28–0.96) and a nonsignificant reduced risk for 
cancer of hypopharynx (OR 0.53, 95% CI 0.28–1.02) and larynx (OR 0.74, 95% CI 0.54–1.01) 
(Table 6). 
 
Table 6.  
ORs by cancer subsite and medical history and medication use 
Variable Subsite (all SCC)a 
 Oral cavity Oropharynx Hypopharynx OP NOSb Larynx Oesophagus P-
valuec 
Skin warts/verrucae 0.76 (0.60–0.95) 
0.88 (0.70–
1.22) 
0.62 (0.42–
0.92) 
0.53 (0.32–
0.87) 
0.85 (0.67–
1.06) 
0.85 (0.59–
1.24) 0.291 
Candida 
albicans/thrush  
0.64 (0.48–
0.87) 
0.91 (0.68–
1.22) 
0.58 (0.33–
1.03) 
0.53 (0.27–
1.03) 
0.89 (0.67–
1.19) 
0.47 (0.26–
0.83) 0.086 
Herpetic lesions 0.97 (0.77–1.23) 
0.97 (0.76–
1.23) 
1.00 (0.69–
1.47) 
0.87 (0.54–
1.39) 
0.98 (0.78–
1.23) 
0.94 (0.65–
1.35) 0.997 
Heartburn 0.88 (0.70–1.09) 
0.89 (0.71–
1.12) 
0.64 (0.44–
0.93) 
0.78 (0.50–
1.24) 
1.05 (0.84–
1.30) 
0.87 (0.61–
1.24) 0.253 
Regurgitation 0.89 (0.67–1.18) 
0.76 (0.56–
1.04) 
0.62 (0.37–
1.06) 
1.07 (0.62–
1.86) 
0.94 (0.72–
1.24) 
1.47 (0.98–
2.21) 0.065 
Medication for 
heartburn 
0.78 (0.61–
1.00) 
0.78 (0.60–
1.01) 
0.45 (0.28–
0.72) 
0.88 (0.54–
1.45) 
0.96 (0.76–
1.22) 
0.72 (0.48–
1.08) 0.076 
Medication for 
regurgitation 
0.76 (0.48–
1.25) 
0.91 (0.56–
1.47) 
0.62 (0.24–
1.59) 
0.67 (0.24–
1.89) 
0.78 (0.49–
1.25) 
0.81 (0.38–
1.75) 0.977 
Aspirin use 1.04 (0.76–1.41) 
1.05 (0.76–
1.46) 
0.53 (0.28–
1.02) 
1.29 (0.70–
2.35) 
0.74 (0.54–
1.01) 
0.51 (0.28–
0.96) 0.042 
 
OR, odds ratio; SCC, squamous cell carcinoma. 
a ORs from multinomial model adjusted for age, gender, education, smoking (pack-years), alcohol 
drinking (drink-years), fruit consumption and body mass index 2 years ago (note: not adjusted for 
centre).  
b Oral, pharynx not otherwise specified.  
c P-value for equality of ORs across subsites.  
 
Analysis by type of controls (hospital or population) showed a significantly decreased risk 
associated with heartburn (OR 0.57, 95% CI 0.39–0.86) and use of medication for heartburn (OR 
0.55, 95% CI 0.37–0.80) when restricted to population controls. There was no association observed 
for hospital controls (P = 0.021 and 0.057 for difference in estimates between types of control, 
respectively) (Table 7). When hospital controls with diseases of the skin and subcutaneous tissue 
were excluded from the analysis for skin warts/verrucae, the OR estimate did not change 
substantially (OR 0.83, 95% CI 0.70–0.99). 
 
Table 7.  
ORs by centres with population and hospital controls 
Variable Centres using hospital controls Centres using population controls (UK only) P-value 
 Casesa Controlsa OR (95% CI)b Casesa Controlsa OR (95% CI)b  
 N (%)  N (%)   N (%)  N (%)    
Skin warts/verrucae 
0.150 Never    949 (65.0) 904 (57.32) 1.00 170 (57.82) 173 (44.36) 1.00 
Ever     511 (35.0) 673 (42.68) 0.84 (0.71–1.00) 124 (42.18) 217 (55.64) 0.58 (0.40–0.85) 
Candida albicans/thrush  
0.822 Never    1207 (83.59) 1191 (75.81) 1.00 250 (85.03) 316 (81.03) 1.00 
Ever     237 (16.41) 380 (24.19) 0.72 (0.58–0.90) 44 (14.97) 74 (18.97) 0.76 (0.45–1.29) 
Herpetic lesions 0.584 
Variable Centres using hospital controls Centres using population controls (UK only) P-value 
 Casesa Controlsa OR (95% CI)b Casesa Controlsa OR (95% CI)b  
 N (%)  N (%)   N (%)  N (%)    
Never    928 (64.13) 903 (57.26) 1.00 147 (50.0) 215 (55.13) 1.00 
Ever     519 (35.87) 674 (42.74) 0.94 (0.79–1.23) 147 (50.0) 175 (44.87) 1.11 (0.77–1.60) 
Heartburn 
0.021 Never    784 (52.97) 847 (54.66) 1.00 148 (50.34) 166 (42.78) 1.00 
Ever     696 (47.03) 725 (45.34) 0.98 (0.83–1.16) 146 (49.66) 222 (57.22) 0.57 (0.39–0.86) 
Regurgitation 
0.490 Never    1189 (80.66) 1273 (80.32) 1.00 250 (85.03) 315 (81.40) 1.00 
Ever     285 (19.34) 312 (19.68) 0.94 (0.76–1.16) 44 (14.97) 72 (18.60) 0.71 (0.43–1.17) 
Medication for heartburn 
0.057 Never    1082 (73.91) 1137 (71.46) 1.00 193 (65.65 223 (57.62) 1.00 
Ever     382 (26.09) 454 (28.54) 0.87 (0.72–1.05) 101 (34.35) 164 (42.38) 0.55 (0.37–0.80) 
Medication for regurgitation 
0.717 Never    1378 (94.58) 1466 (93.02) 1.00 277 (94.22) 351 (90.70) 1.00 
Ever     79 (5.42) 110 (6.98) 0.84 (0.59–1.19) 17 (5.78) 36 (9.30) 0.72 (0.36–1.45) 
Aspirin use 
0.603 Never    1298 (88.42) 1364 (86.22) 1.00 229 (77.89) 285 (73.45) 1.00 
Ever     170 (11.58) 218 (13.78) 0.91 (0.70–1.16) 65 (22.11) 103 (26.55) 0.93 (0.60–1.46) 
 
CI, confidence interval; OR, odds ratio. 
a Numbers do not add up to total due to missing values.  
b Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), 
fruit consumption and body mass index 2 years ago.  
 
Discussion 
This international multicentre case–control study is the largest to date investigating the role of 
medical history and medication use in the aetiology of UADT cancers. A history of infections such 
as warts/verrucae or C. albicans infection/thrush was associated with decreased risk of UADT 
cancer, while there was no association found for herpetic lesions, symptoms of gastro-oesophageal 
reflux or regular aspirin use. However, the associations varied by subsite within the UADT.  
Considering methodological quality, firstly, the study has included cancers over several sites in the 
UADT. While these are a heterogeneous group of neoplasms, they have similar aetiologies: Regular 
alcohol consumption and tobacco smoking are established causes of these cancers [3, 4]. However, 
to investigate potential aetiological differences, we conducted additional analyses by subsite. 
Secondly, while this study was conducted in 10 countries across Europe, all participating centres 
followed a similar protocol and used the same questionnaire. This enabled us to take into account in 
the analyses potential confounding factors such as smoking, alcohol intake, fruit consumption and 
BMI. Thirdly, while the overall sample size was large, the study did not have the statistical power to 
examine whether the effects varied between countries. Finally, because three centres (in a single 
country) used population controls, we carried out additional analysis separately for hospital and 
population controls.  
Our results show that having a history of warts/verrucae was associated with a reduced risk for 
UADT cancers, irrespective of location. This effect was more evident for cancers of oral cavity, 
hypopharynx and oral/pharynx cancers with site ‘not otherwise specified’. The effect was also 
similar for all UADT subsites, but was more evident in centres with population controls. A possible 
explanation for this is that eligible control admission diagnoses included skin diseases for hospital 
controls. However, the proportion of hospital controls with diseases of the skin and subcutaneous 
tissue was small and exclusion of hospital controls with these diseases did not substantially change 
the OR estimate. These findings contradict previous studies, which have not reported any 
associations: Maden et al. [21] reported an OR of 1.30, 95% CI (0.7–2.4) for oral cancer in men for 
common warts and an OR of 0.9, 95% CI (0.2–2.4) for genital warts; Talamini et al. [17] reported 
an OR for oral cancer of 1.0, 95% CI (0.5–2.3) for hand and feet warts and an OR of 0.5, 95% CI 
(0.1–1.6) for other sites; Garrote et al. [16] reported an OR of 1.04, 95% CI (0.43–2.50) for warts 
on hands and feet and an OR of 0.72, 95% CI (0.44–1.18) for other sites for cancer of the oral 
cavity and oropharynx.  
The explanation for a reduced risk of warts on UADT cancer is not clear. The effect was evident for 
all locations, despite the fact that the warts are caused by different types of HPV. For example, 
common warts are caused mostly by HPV types 2 and 4, while anogenital warts are commonly 
caused by HPV types 6 and 11. HPV types 16, 18 and others have been associated with cancer [12].  
A history of C. albicans (thrush) infection in our study was also associated with a reduced risk for 
UADT cancers, irrespective of location. This effect was more evident for cancers of oral cavity and 
oesophagus. Talamini et al. [17] in contrast found a significant risk for cancers of the oral cavity 
and oropharynx (OR 6.5, 95% CI 1.2–34.4) for oral candidosis and an increased but not significant 
risk (OR 2.0, 95% CI 0.7–5.8) for candidosis in other body sites, however Garrote et al. [16] found 
no association. While thrush is an acute infection, it has been suggested that malignant 
transformation of oral leukoplakia may be elicited by particular biotypes of C. albicans and that 
yeasts could play a causal role in oral cancer by means of endogenous nitrosamine production [15].  
In agreement with previous studies [14, 17, 21, 31], we did not find a significant association 
between previous herpetic infection and UADT cancers. However, two studies have reported 
significant protective effect: Garrote et al. [16] (OR 0.36 95% CI 0.17–0.75) for herpetic lesions 
and cancer of oral cavity and oropharynx and Rosenquist et al. [26] for a history of herpes labialis 
for oral cancer (OR 0.5, 95% CI 0.3–0.9). It has been previously suggested that patients with oral 
cancer have an increased immune response to HSV [20]. Laboratory experiments have shown that 
HSV can be carcinogenic or cocarcinogenic [32]. However, later epidemiological studies did not 
support these observations.  
Overall, we did not find an association for symptoms of gastro-oesophageal reflux (heartburn or 
regurgitation) and risk of UADT cancer, which is similar to results reported by D’Souza et al. [9] 
for oropharyngeal cancer (OR 1.0, 95% CI 0.5–1.7). However, regurgitation was associated with a 
nonsignificant increased risk for cancer of oesophagus. A study in Sweden [19] of 189 cases of 
oesophageal SCC and 820 controls did not find an association with symptoms of reflux, irrespective 
of the frequency, severity or duration of the symptoms (OR 1.1, 95% CI 0.7–1.9). However, strong 
relationships have been reported between gastro-oesophageal reflux and oesophageal 
adenocarcinoma [18, 19]. Analysis by type of controls (hospital or population) showed a 
significantly decreased risk associated with heartburn and medication for heartburn, only when 
using population controls. This may be accounted for by the increased morbidity among hospital 
controls masking such an association. However, in this study 45% of hospital controls and 57% of 
population controls reported heartburn.  
While our study overall did not show a significant association between regular aspirin use and risk 
of UADT cancer, when considered by subsite, aspirin was associated with a reduced risk for cancer 
of oesophagus and a nonsignificant reduced risk for cancers of hypopharynx and larynx. This 
finding supports results of a review of aspirin and cancer risk [23], which showed that aspirin use 
was associated with a reduced risk of cancer of the oesophagus. Combined data from three Italian 
case–control studies showed that aspirin use was associated with reduced risk of cancers of the 
UADT (OR 0.33, 95% CI 0.13–0.82 for duration of use of >5 years) [25]. Analysis of individual 
patient data from eight randomised trials of daily aspirin versus no aspirin [24] showed a significant 
reduction in death due to cancer (OR 0.79, 95% CI 0.68–0.92). There were no data reported 
specifically on head and neck cancer, but there was a nonsignificant decrease in risk of death due to 
oesophageal cancer [hazard ratio (HR) 0.78 (95% CI 0.27–2.23) for 0–5 years of follow-up and HR 
0.43 (95% CI 0.11–1.72) for 5 years follow-up or longer]. The overall protective effect of aspirin 
was more evident for adenocarcinomas (HR 0.53, 95% CI 0.35–0.81 for 5 years of follow-up or 
longer). The protective effect of aspirin in this combined analysis did not appear to increase at doses 
>75 mg daily.  
In the current study, we did not collect information on dose and defined regularly as at least once 
per week for a year. We also did not collect information on reasons for regularly taking aspirin. 
Aspirin is widely used for pain relief and also most commonly used for primary and secondary 
prevention of vascular disease. However, its use is associated with gastrointestinal and extracranial 
bleeds. When recruiting hospital controls, admission diagnoses related to alcohol, tobacco or dietary 
practises were excluded, but diagnoses related to musculoskeletal, gastrointestinal and circulatory 
diseases were included [29]. It may be therefore that aspirin use is particularly high in the hospital 
control populations chosen and this might artificially increase the observed protective effect. We 
therefore carried out a separate analysis for centres with population- and hospital-based controls and 
found no statistically significant difference in risk associated with aspirin use. We also noted that a 
higher proportion of controls stopped taking aspirin within a year before interview compared with 
cases.  
 
Conclusions 
In this largest study conducted on the role of infections on UADT cancers, we have reported that 
some infections appear to be a marker for decreased risk. The role of medical factors and 
medication use varied with UADT subsites with aspirin use associated with a decreased risk of 
oesophageal cancer and suggestive of a decreased risk of hypopharyngeal and laryngeal cancers. 
These findings are important in terms of understanding the aetiology of UADT cancers and should 
be a priority for further investigation using collaboration between major studies (e.g. INHANCE 
[33]).  
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